Akeso is a clinical-stage biopharmaceutical company committed to in-house discovery, development and commercialization of first-in-class and best-in-class therapies. The company is dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. The company’s business is designed to drive success through both efficient and breakthrough R&D innovation. The company believes that fully integrated in-house R&D capabilities are critical to achieving success in China. Through its Akeso Comprehensive Exploration platform (“ACE Platform”), the company consistently and rapidly innovated and produced high quality drug candidates, with minimal dependence on external vendors, and have achieved remarkable results and industry recognition.